Quantitative determination of benazepril and benazeprilat in human plasma by gas chromatography-mass spectrometry using automated 96-well disk plate solid-phase extraction for sample preparation

An analytical method for the determination of benazepril and its active metabolite, benazeprilat, in human plasma by capillary gas chromatography-mass-selective detection, with their respective labelled internal standard, was developed and validated according to international regulatory requirements. After addition of the internal standards, the compounds were extracted from plasma by solid-phase extraction using automated 96-well plate technology. After elution, the compounds were converted into their methyl ester derivatives by means of a safe and stable diazomethane derivative. The methyl ester derivatives were determined by gas chromatography using a mass-selective detector at m/z 365 for benazepril and benazeprilat and m/z 370 for the internal standards. Intra- and inter-day accuracy and precision were found to be suitable over the range of concentrations between 2.50 and 1000 ng/mL.     

赖诺普利与贝那普利治疗高血压合并脑卒中的疗效及对血清ADMA水平的影响

目的:探讨赖诺普利与贝那普利治疗高血压合并脑卒中的疗效及对血清非对称性二甲基精氨酸(ADMA)水平的影响,以期为高血压合并脑卒中的治疗提供指导。方法:选取2014年1月-2016年3月在我院确诊并接受治疗的高血压合并脑卒中246例,按随机数字表法将患者随机分为研究组、对照组和常规组,每组各82例。常规组采用基础治疗,研究组采用基础治疗联合赖诺普利治疗,对照组采用基础治疗联合贝那普利治疗。比较3组患者治疗前后血压参数、血清ADMA和Hcy水平、治疗效果和不良反应。结果:治疗前三组患者的血压参数(SBP、DBP和PP)、血清ADMA和Hcy水平、m RS评分均无显著差异;治疗后三组患者上述指标水平较治疗前均显著降低(P0.05),且研究组患者指标水平明显低于对照组和常规组(P0.05)。研究组治疗有效率明显高于对照组和常规组,对照组治疗有效率明显高于常规组,上述差异均具有统计学意义(P0.05)。三组患者不良反应率无显著差异(P0.05)。结论:赖诺普利和贝那普利均能有效降低高血压合并脑卒中患者血压水平,改善血管内皮功能,疗效显著;但赖诺普利的效果要比贝那普利更好,更值得临床推广。     

贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床疗效

目的:探讨贝那普利联合阿托伐他汀治疗慢性心力衰竭临床疗效及对患者血清炎症因子水平的影响。方法:收集我院2014年12月~2016年5月确诊为慢性心力衰竭的患者120例,随机分为观察组和对照组,各60例。对照组采用口服贝那普利治疗,观察组采用贝那普利联合阿托伐他汀治疗。观察并比较两组患者治疗前后左室收缩末期容积指数(LVESVI)、左室舒张末期容积指数(LVEDVI)、左心室舒张末期内径(LVEDD)、左心射血分数(LVEF)及血清NT-proBNP,hs-CRP,TNF-α,白介素-6(IL-6)及白介素-8(IL-8)水平的变化情况。结果:观察组有效率优于对照组,差异具有统计学意义(P0.05);治疗后,两组患者Pro-BNP、LVEDD、E/A均降低,且观察组低于对照组(P0.05);治疗后,两组患者LVEF升高,且观察组高于对照组(P0.05);两组患者治疗后血清hs-CRP,TNF-α,IL-6及IL-8水平均降低,且观察组低于对照组(P0.05)。结论:贝那普利联合阿托伐他汀治疗对慢性心力衰竭患者进行治疗,疗效显著,患者炎症反应小,是一种安全有效的治疗方法。